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Most cases of human hepatocellular carcinoma develop after persistent chronic 
infection with human hepatitis B virus or hepatitis C virus, and host responses are 
presumed to have major roles in this process.  To recapitulate this process, we have 
developed the mouse model of hepatocellular carcinoma using hepatitis B virus surface 
antigen transgenic mice.  In order to identify the genes associated with 
hepatocarcinogenesis in this model, we compared the gene expression patterns between 
pre-malignant lesions surrounded by hepatocellular carcinoma tissues and control liver 
tissues by using a fluorescent differential display analysis.  Among the genes which 
were expressed differentially in the pre-malignant lesions, we focused on Pim-3, a 
member of a proto-oncogene Pim family, because its contribution to 
hepatocarcinogenesis remains unknown.  Moreover, the unavailability of the 
nucleotide sequence of full-length human Pim-3 cDNA prompted us to clone it from the 
cDNA library constructed from a human hepatoma cell line, HepG2.  The obtained 
2,392 bp human Pim-3 cDNA encodes a predicted open reading frame consisting of 326 
amino acids.  Pim-3 mRNA was selectively expressed in human hepatoma cell lines, 
but not in normal liver tissues.  Moreover, Pim-3 protein was detected in human 
hepatocellular carcinoma tissues and cell lines but not in normal hepatocytes.  
Furthermore, cell proliferation was attenuated and apoptosis was enhanced in human 
hepatoma cell lines by the ablation of Pim-3 gene with RNA interference.  These 
observations suggest that aberrantly expressed Pim-3 can cause autonomous cell 




 Hepatocellular carcinoma (HCC) ranks the eighth cause of death among human 
cancers and is endemic in Asia, Africa, and southern Europe.  Most cases of HCC arise 
from persistent chronic infection with human hepatitis B virus (HBV) or hepatitis C 
virus (HCV)1.  Host responses are presumed to be involved in the development of 
HCC among patients harboring HBV or HCV, because these viruses lack apparent 
oncogenes and the infected patients develop HCC after suffering from chronic 
hepatitis-related pathology2, 3. 
Hepatitis virus infection induces the generation of virus antigen-specific 
cytotoxic T lymphocytes, which have been implicated in both the eradication of viruses 
and liver injury4.  Cycles of cytotoxic T lymphocyte-mediated liver cell destruction 
and regeneration are thought to prepare the mitogenic environment4, 5.  In order to 
elucidate the molecular and cellular mechanism of HCC initiation and development, one 
of us (Y. Nakamoto) has established a mouse model of HCC by using HBV surface 
antigen (HBsAg) transgenic mice (HBsTg)6.  In this model, bone marrow cells and 
splenocytes were obtained from syngeneic wild-type mice, which were immunized with 
HBsAg and were transplanted into HBsTg mice, which were myeloablated beforehand.  
At 15 months after the transplantation, the transgenic mice developed multiple foci of 
HCC surrounded by non-malignant areas consisting of hepatocytes with atypical 
nuclear configuration6, 7. 
To obtain the molecular insights on hepatocarcinogenesis, we compared the 
gene expression pattern between non-tumor portion of this model as a pre-malignant 
lesion and normal tissues by using a fluorescent differential display (FDD) analysis.  
We observed that several genes are expressed differentially in this pre-malignant lesion, 
compared with normal liver tissues.  Of interest is that the gene expression of Pim-3, 
originally identified as depolarization-induced gene in a rat pheochromocytoma cell 
line8, was enhanced in this pre-malignant lesion.  Here, we demonstrated that Pim-3 
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was expressed aberrantly in human HCC tissues and hepatoma cell lines but not normal 
liver tissues.  We also provided evidence to suggest the involvement of Pim-3 in the 
proliferation of human hepatoma cell lines.  
6 
MATERIALS AND MATHODS 
 
Experimental animals 
HBsAg transgenic mouse lineage 107-5D (official designation 
Tg[Alb-1,HBV]Bri66; inbred B10D2, H-2d) was provided by Dr. F. V. Chisari (The 
Scripps Research Institute, La Jolla, CA)9.  Lineage 107-5D contains the entire HBV 
envelope-coding region (subtype ayw) under the transcriptional control of the mouse 
albumin promoter, and expresses the HBV small, middle, and large envelope proteins in 
their hepatocytes9.  They display no evidence of liver disease during their lifetime 
unless they receive the adoptive transfer of HBsAg-specific cytotoxic T lymphocytes9, 
due to their immunological tolerance to the HBs transgene at the T cell level10.  
Chronic hepatitis-related liver disease model was generated as described 
previously6.  Briefly, after male HBsAg transgenic mice were thymectomized and 
irradiated (900 cGy), their hematopoietic system was reconstituted with the bone 
marrow cells from syngeneic non-transgenic B10D2 (H-2d) mice.  At 1 week after the 
bone marrow transplantation, the animals received 108 splenocytes from syngeneic 
non-transgenic B10D2 (H-2d) mice that were infected intraperitoneally with a 
recombinant vaccinia virus expressing HBsAg 3 wk before the splenocyte transfer.  At 
12 to 15 months after the lymphocyte transfer, multiple HCC foci developed in mice6, 7.  
Non-tumor and tumor portions were demarcated macroscopically and were removed 
separately.  A pathologist without a prior knowledge on the experimental procedures 
confirmed the presence of hepatocytes with atypical configurations but not malignant 
cells in this non-tumor potion.  Hence, non-tumor portions were designated as 
pre-malignant lesions in the following experiments.  Liver tissues were also obtained 
from untreated or HBsTg mice transplanted with tolerant splenocytes as a control. 
Fluorescent differential display 
Total RNAs extracted from liver tissues were subjected to FDD according to 
the method described by Ito and colleagues11.  Briefly, total RNAs were isolated with 
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RNA-Bee (Biotecx Laboratories, Inc.), followed by the treatment with RNase-free 
DNase (Takara Shuzo, Kyoto, Japan).  The purified total RNAs (2.5 µg) were 
reverse-transcribed with SuperScript II reverse transcriptase (Invitrogen) and 
fluorescein-labeled anchor primer, GT15A, GT15C, or GT15G.  The resultant cDNA 
equivalent to 50 ng of RNA was subjected to polymerase chain reaction (PCR) with 0.5 
µM anchor primer, 0.5 µM arbitrary primer (10 mer kit A; Operon), 50 µM each dNTP, 
1 unit of Gene Taq DNA polymerase (Nippon Gene, Toyama, Japan), and 1 unit of Taq 
DNA polymerase (Takara Shuzo).  PCR products were separated with 6% 
polyacrylamide-8 M urea gel and analyzed by employing Vistra Fluor Imager SI 
(Molecular Dynamics).  The bands of interest were excised from the gel and cloned 
into pSTBlue-1 Vector (Novagen).  The inserted cDNA was sequenced with CEQ 2000 
DNA Analysis System (Beckman Coulter) and analyzed with the BLAST program to 
search the GeneBank database. 
Cell culture 
Human hepatoma cell lines (HepG2, Hep3B, HLE, HLF, HuH7, and SK-Hep1) 
were maintained in Dulbecco’s modified Eagle’s medium (DMEM; Sigma) 
supplemented with 10% heat-inactivated fetal bovine serum (FBS; Atlanta Biologicals, 
Norcross, Ga.) at 37 oC in a humidified atmosphere with 5% CO2 in the air12. 
Semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) 
Total RNAs were isolated with RNA-Bee (Biotecx Laboratories, Inc.), 
followed by the treatment with RNase-free DNase (Takara Shuzo, Kyoto, Japan), and a 
semi-quantitative RT-PCR analysis was performed as described previously13.  The 
cDNA was amplified using the sets of the primers that specifically amplify Pim family 
kinases and glyceraldehyde 3-phosphate dehydrogenase (GAPDH).  The sequences are 
as follows; Pim-1, sense 5’-CCCGAGCTATTGAAGTCTGA-3’, antisense 
5’-CTGTGCAGATGGATCTCAGA-3’; Pim-2, sense 
5’-CATCCCCAGCAGCTCTTTAG-3’, antisense 
5’-CAGTAGGGTCCCTCACCAAA-3’; Pim-3, sense 
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5’-AAGCAGTGACCTCTGACCCCTGGTGACC-3’, antisense 
5’-CAGCGGAACCGCTCATTGCCAATGG-3’; GAPDH, sense 
5’-ACCACAGTCCATGCCATCAC-3’, antisense 
5’-TCCACCACCCTGTTGCTGTA-3’.  The resultant PCR products were separated on 
1.5% agarose gel and visualized by ethidium bromide staining.  The band intensities 
were measured using NIH Image Analysis Software Ver 1.61 (National Institutes of 
Health, Bethesda, MD) and the ratios to GADPH were calculated. 
cDNA library construction and screening 
Total RNA was isolated from HepG2 cell line and polyA mRNA was separated 
by OligotexTM-dT30 <Super> mRNA Purification kit (Takara Shuzo).  cDNA was 
synthesized with SuperScript II reverse transcriptase (Invitrogen) and oligo-dT primer, 
and cDNA library was constructed in pCMVSPORT6 (Invitrogen) with Escherichia coli 
DH10B (Invitrogen), according to the manufacturer’s instructions.  The initial 
screening was performed using GENE TRAPPER® cDNA Positive Selection System 
(Invitrogen) and the oligomer, CTGTGAAGCACGTGGTGAAG, as a probe.  The 
obtained colonies were subjected to colony PCR screening with the sets of primers 
described above.  The inserted cDNA was sequenced with CEQ 2000 DNA Analysis 
System (Beckman Coulter). 
Northern blot analysis 
Human Pim-3 mRNA expression was analyzed by using Human 12-Lane 
MTNTM Blot (Clontech, Palo Alto, CA).  In vitro transcribed digoxigenin-labeled 
probes were hybridized overnight at appropriate temperatures (70 oC for Pim-3 and 68 
oC for GAPDH).  After being washed sequentially each for 15 min in 2 x and 0.5 x 
SSC buffer containing 0.1% sodium dodecyl sulfate at room temperature and at 68 oC, 
respectively, the hybridized probes were detected by the DIG detection kit (Boehringer 
Mannheim Biochemicals), according to the manufacturer’s instructions. 
Preparation of anti-Pim-3 polyclonal antibodies 
Anti-Pim-3 antibodies were prepared by Asahi Techno Glass Co. (Tokyo, 
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Japan).  Briefly, two chickens were immunized with keyhole limpet 
hemocyanine-conjugated Pim-3 peptide, CGPGGVDHLPVKILQPAKAD, which 
corresponds to the amino acid residues between 13 and 32 in human Pim-3 and is 
conserved in murine Pim-3, and their egg yolks were harvested before and after the 
immunization.  IgY proteins were purified with EGGstract® IgY Purification System 
(Promega) according to the manufacturer’s instructions, and they were affinity-purified 
with Pim-3 peptide conjugated NHS-activated HP (Amersham Biosciences, Tokyo, 
Japan).  Purified antibodies were quantified by measuring the absorbance at 280 nm. 
Immunohistochemical analysis 
Human liver specimens were surgically obtained from the patients with their 
informed consent, and mouse liver tissues were obtained from HBsTg mouse at the 
indicated time intervals after splenocyte transfer.  Paraffin-embedded tissue sections 
were deparaffinized in xylene and rehydrated through graded concentrations of ethanol 
(100% - 70%).  After incubation with 0.3% hydrogen peroxide in 10 mM phosphate 
buffer, pH 7.4, containing 150 mM NaCl (phosphate buffered saline; PBS (-)), sections 
were incubated sequentially with 3% normal rabbit serum (DAKO, Kyoto, Japan) and 
2% bovine serum albumin (BSA) in PBS (-) and with Avidin-Biotin blocking kit (Vector 
Laboratories).  Subsequently, the slides were treated with 10 µg/ml anti-Pim-3 IgY or 
pre-immunized IgY at 4 oC overnight, followed by the incubation with 2.5 µg/ml 
biotin-conjugated rabbit anti-chicken IgY antibodies (Promega) at room temperature for 
30 min.  The immune complexes were visualized by using the Vectastain Elite ABC kit 
(Vector Laboratories) and Vectastain DAB substrate kit (Vector Laboratories) according 
to the manufacturer’s instructions.  The slides were counterstained with hematoxylin 
(DAKO), mounted, and observed under a microscope (BX-50; Olympus, Tokyo, Japan). 
Immunocytochemical analysis of HuH7 cells 
Cells were cultured on Lab-Tec chamber slides (Nalge Nunc, Roskide, 
Denmark).  They were fixed with 4% paraformaldehyde in PBS (-) and permeated in 
methanol.  Then, they were blocked by incubation with 3% normal rabbit serum and 
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2 % BSA in PBS (-) at room temperature for 30 min, and with Avidin-Biotin blocking 
kit.  Subsequently, they were treated with 20 µg/ml affinity-purified anti-Pim-3 IgY or 
pre-immunized IgY at 4 oC overnight, with 2.5 µg/ml biotin-labeled rabbit anti-chicken 
IgY at room temperature for 30 min.  The signals were amplified and visualized by the 
Vectastain Elite ABC kit and Vectastain DAB substrate kit according to the 
manufacturer’s instructions.  The slides were counterstained with methylgreen 
(DAKO), mounted, and observed under a microscope (BX-50; Olympus).  
RNA interference (RNAi) 
Short interfering RNA (siRNA) was synthesized with SilencerTM siRNA 
Construction Kit (Ambion) according to the manufacturer’s instructions.  By 
employing siRNA Target Finder and Design Tool (Ambion), siRNA duplexes were 
designed to target AA(N19)UU sequences in the open reading frame of mRNA encoding 
Pim-3.  The selected siRNA target sequence (5’-GCACGUGGUGAAGGAGCGG-3’ 
corresponding to 642-661) was further subjected to BLAST searches against other 
human genome sequences to ensure its target specificity.  We identified two distinct 
cDNAs, which exhibit identity with the target sequence at 16 out of 19 nucleotides.  
However, we could not detect any specific bands corresponding to these cDNAs in 
HuH7 and Hep3B cell lines by RT-PCR analysis (our unpublished data), further 
indicating the specificity of the used target sequence.  Scramble siRNA 
(5’-GCGCGCUUUGUAGGAUUCG-3’ designed by B-Bridge International, inc.) was 
used as a negative control.  Each siRNA duplex (final concentration 50 nM) was mixed 
with 12.5 µl and 12 µl of Lipofectamine 2000 (Invitrogen) for HuH7 and Hep3B, 
respectively.  The mixtures were added into 2.5 ml of Opti-MEM (Invitrogen) and 
allowed to stand at room temperature for 20 min.  The final mixture was then added 
directly into the semi-confluent cells in 6-cm culture dishes, which were washed with 
serum-free DMEM beforehand.  The following day, 2.5 ml of DMEM plus 20% FBS 
medium was added to adjust the FBS concentration to 10%.  At the indicated time 
intervals, cells were harvested for further analyses. 
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Semi-quantitative RT-PCR analysis of siRNA transfectant 
Hep3B and HuH7 cells were harvested at 2 and 4 days after the transfection, 
respectively.  Total RNAs were extracted and a semi-quantitative RT-PCR analysis was 
performed as described above.  The cDNA was amplified using the sets of the primers 
that specifically amplify Pim-3 (sense 
5’-ATGCTGCTCTCCAAGTTCGGCTCCCTGGCG-3’, antisense 5’- 
TCCTGTGCCGGCTCGGGTCGCTCCAGCACC-3’) and GAPDH. 
Cell proliferation assay 
Cells were trypsinized at 2 days after the transfection, and 5 x 103 cells were 
plated to each well of 96-well plate.  This time point was designated as day 0.  The 
cell viability was determined every day using WST-1 reagent (an MTT analog from 
Boehringer Mannheim Biochemicals) according to the manufacturer’s instructions.  
The ratios to day 0 were calculated. 
Cell cycle analysis by a flow cytometry 
HuH7 cells were harvested at 4 days after the transfection and fixed with 
graded concentrations of ethanol on ice.  Then, they were incubated with 50 µg/ml 
propidium iodide and 1 µg/ml of RNase A for 30 min at room temperature, and 
quenched by adding EDTA to a final concentration of 10 µM.  The filtered cells were 
analyzed using a FACSCaliber (Becton Dickinson, Bedford, Mass.).  The distribution 
in each cell cycle phase was determined by using Cell Quest analysis software (Becton 
Dickinson). 
Chromatin condensation analysis by Hoechst 33258 
HuH7 and Hep3B cells were harvested at 4 days after the transfection and 
stained with Hoechst 33258 in order to detect the cells with condensed nuclei under a 




Identification of the genes differentially expressed in pre-malignant liver tissue 
We compared the gene expression patterns between pre-malignant lesions and 
normal liver tissues by employing a FDD method.  The determination of the nucleotide 
sequence of the resultant bands identified 24 and 19 distinct genes among the 
up-regulated and down-regulated bands in pre-malignant lesions, respectively (Table 1).  
Among these genes, Pim-3 expression has not been reported in normal hepatocytes.  
Hence, we focused on Pim-3, a member of proto-oncogene Pim family including Pim-1 
and Pim-2.  A semi-quantitative RT-PCR analysis confirmed that Pim-3 mRNA 
expression was significantly enhanced in the pre-malignant tissues and to a lesser 
degree, in HCC tissues, compared with control (Fig. 1).  In contrast, specific Pim-1 
and Pim-2 transcripts were barely detected under these conditions (Fig. 1).  These 
results indicate that Pim-3 mRNA expression is enhanced during HCC development in 
this model. 
We further localized Pim-3 protein immunohistochemically in liver tissues 
obtained from HBsTg mouse after splenocyte transfer.  We failed to detect Pim-3 
protein in unmanipulated mice (Fig. 2A) or 9 month after splenocyte transfer, when 
hepatocytes with atypical nuclear configuration were not detected (data not shown).  
On the contrary, Pim-3 protein was weakly detected in the cytoplasm of hepatocytes 
with atypical nuclear configurations in pre-malignant lesion (Fig. 2B and E) and highly 
differentiated neoplastic hepatocytes in the tumor portion7 (Fig. 2C and F).  Moreover, 
Pim-3 protein was detected in regenerated proliferating bile ductules (Fig. 2D, arrow), 
which are assumed to be the proliferation of hepatic stem cells after the chronic liver 
injury such as infection and tumor14.  These results may indicate that Pim-3 protein 
expression was aberrantly enhanced in liver during the course of hepatocarcinogenesis 
in this model. 
Cloning and determination of nucleotide sequence of human Pim-3 
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Because the full length human Pim-3 cDNA nucleotide sequence has not been 
determined yet, we initially cloned and determined the nucleotide sequence of human 
Pim-3 cDNA by screening cDNA library constructed from a human hepatoma cell line, 
HepG2.  Three positive clones were obtained after two rounds of screening, and these 
three distinct cDNA clones contained the same insertion, which consists of 2,392 bp.  
The 5’-untranslated region is 82.3 % G and C, while the 3’-untranslated region contains 
5 copies of the ATTTA motif and 8 copies of TATT motif (Fig. 3A).  This sequence 
exhibits an identity with a partial human Pim-3 cDNA sequence predicted from EST 
database (data not shown) 15.  Its open reading frame encodes the protein consisting of 
326 amino acids with a calculated molecular weight of 35,861 (Fig. 3A).  Moreover, 
the amino acid sequence of the predicted open reading frame, shares a high degree of 
identity with the mouse16 and rat Pim-3 (KID-1) 8 proteins (95.0 %; Fig. 3B).  Based 
on these results, we judged this clone as human Pim-3 cDNA.  Human Pim-3 protein 
showed a high sequence identity with the quail qPim17 (73.9 %) and Xenopus Pim 
(Pim-1) 18 (68.7 %) at the amino acid level (data not shown).  Moreover, human Pim-3 
protein shows a high sequence identity with human Pim-119 (57.1 %) and Pim-220 
(44.0 %) at the amino acid level (Fig. 3C).  Northern blotting analysis detected 2.4-kb 
mRNA in various organs including heart, skeletal muscle, brain, spleen, kidney, 
placenta, lung, and peripheral blood leukocytes (Fig. 4).  In contrast, no specific band 
was detected in colon, thymus, liver, and small intestine under the present experimental 
conditions (Fig. 4). 
Pim-3 is expressed aberrantly in human HCC 
Immunohistochemical analysis failed to detect Pim-3 protein in normal liver 
tissues (Fig. 5A), consistent with the Northern blotting analysis.  On the contrary, 
Pim-3 protein was weakly but diffusely detected in most of large regenerative nodules 
and  adenomatous hyperplasia, lesions with precancerous potential, which were 
located adjacent to HCC areas (19 of 27 cases; Fig. 5B and 5C).  Moreover, a 
substantial proportion of HCC cells were immunostained with anti-Pim-3 IgY (6 of 27 
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cases; Fig. 5D and 5E) but not the pre-immunized IgY (data not shown).  Furthermore, 
Pim-3 protein was observed markedly in regenerated proliferating bile ductules (27 of 
27 cases; Fig. 5C and 5F, arrows).  Because the staining patterns were similar to that 
observed in HBsTg mouse model (see Fig 2), these results would indicate that Pim-3 
protein expression was aberrantly enhanced in precancerous lesion, also in humans, and 
a portion of HCC cells. 
Constitutive Pim-3 expression in human hepatoma cell lines 
Immunohistochemical analysis indicated that Pim-3 protein expression was 
aberrantly enhanced not only in precancerous lesion but also in a portion of HCC cells 
in human HCC tissues (Fig. 5).  This finding prompted us to examine Pim-3 
expression in human hepatoma cell lines, by RT-PCR.  To exclude the possibility that 
contaminated genomic DNA gave rise to the generation of the amplified bands, we used 
total RNA samples that were treated with DNase.  Under the present condition, Pim-3 
transcript was detected in all hepatoma cell lines, whereas no specific band was detected 
in the normal liver tissue (Fig. 6A), consistent with the Northern blotting analysis.  The 
exclusion of reverse transcriptase failed to give rise to any bands, further indicating the 
specificities of RT-PCR (Fig. 6A non-RT).  Moreover, an immunocytochemical 
analysis detected immunoreactive Pim-3 proteins in HuH7 cell line, when incubated 
with anti-Pim-3 antibodies (Fig. 6B-a) but neither pre-immunized IgY (Fig. 6B-b) nor 
anti-Pim-3 adsorbed with the relevant peptide (Fig. 6B-c).  Immunoreactive Pim-3 
proteins were similarly detected in all six human hepatoma cell lines, consistent with 
RT-PCR analysis (data not shown).  Collectively, these results would indicate that 
Pim-3 was constitutively expressed in human hepatoma cell lines. 
RNAi ablation of Pim-3 induces cell death to hepatoma cell lines 
Because Pim-1 and Pim-2 were required to induce cell cycle progression21, 22 
and anti-apoptotic effects21-25, we next examined the role of Pim-3 in cell proliferation, 
by ablating endogenous Pim-3 mRNA expression in HuH7 and Hep3B cell lines with 
RNAi.  Endogenous Pim-3 mRNA level was decreased after the transfection with 
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specific Pim-3 siRNA but not Scramble siRNA (Fig. 7A).  Under these conditions, 
transfection with Pim-3 siRNA significantly retarded cell proliferation, compared with 
Scramble siRNA-transfected and the control cells (Fig. 7B and C).  These results 
suggested that Pim-3 ablation has adverse effects on the proliferation of hepatoma cell 
lines.  We further observed that HuH7 cells detached from the plates later than 4 days 
after the transfection with Pim-3 but not Scramble siRNA (Fig. 8A).  Moreover, Pim-3 
siRNA transfectants exhibited a higher ratio of sub-G1 populations with reduced G1 and 
G2/M populations, compared with Scramble siRNA transfectants and control cells (Fig. 
8B).  Furthermore, the proportion of cells with condensed nuclei was significantly 
higher in both HuH7 and Hep3B cells transfected with Pim-3 siRNA, than those 
transfected with Scramble siRNA (Fig. 8C).  These observations would indicate that 




 Transcriptome analysis has been widely applied to elucidate molecular 
mechanisms of various types of diseases and can provide many important clues, 
particularly for understanding the molecular pathogenesis of oncogenesis, where the 
expression of many genes changes simultaneously26, 27.  Several independent groups 
performed transcriptomal studies on human HCC28-33.  However, in most studies, the 
gene expression pattern was compared between tumor and non-tumor portions obtained 
from the same patients28-33.  Because these non-tumor portions exhibit usually 
hepatocyte dysplasia, this type of analysis may fail to detect the changes in gene 
expression that have already existed at the stage of hepatocyte dysplasia.  In order to 
circumvent these pitfalls, we compared gene expression patterns between pre-malignant 
lesions and normal tissues by using FDD.  We observed that various genes were 
selectively changed in pre-malignant lesions.  Moreover, a semi-quantitative RT-PCR 
analysis did not detect any significant differences in the expression of several of these 
genes between malignant and pre-malignant lesions (our unpublished data), supporting 
our assumption that the changes in gene expression which have already existed at the 
stage of hepatocyte dysplasia, might be undetected in the preceding studies. 
Among the genes identified in this study, we focused on Pim-3.  Pim-3 was 
originally identified as depolarization-induced gene KID-1 in PC12 cell line, a rat 
pheochromocytoma cell line8.  Subsequently, several independent groups observed a 
selective expression of its mRNA in neuronal system16, 34, 35, but not liver.  By using 
human Pim-3 cDNA as a probe, we detected Pim-3 mRNA in several organs such as 
brain and spleen, but not liver.  On the contrary, Pim-3 mRNA expression was detected 
in all human hepatoma cell lines that we examined.  Moreover, immunohistochemical 
analysis detected immunoreactive Pim-3 protein in precancerous lesions and a portion 
of HCC cells.  Furthermore, Pim-3 protein was also detected in regenerating bile 
ductules, which are assumed to be the proliferation of hepatic stem cells after the 
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chronic liver injury such as infection and tumor14.  Liver cell destruction and 
regeneration are thought to prepare the mitogenic, mutagenic environment, and 
impaired liver regeneration leading to HCC development36.  Thus, Pim-3 expression 
may aberrantly be enhanced from hepatocyte regeneration process to its malignant 
transformation. 
 Deneen and colleagues provided evidence on the crucial involvement of Pim-3 
in EWS/ETS-mediated malignant transformation of mouse NIH 3T3 cells37.  They 
demonstrated that Pim-3 was a common transcriptional target of EWS/ETS.  
EWS/ETS fusion proteins retain an intact ETS DNA-binding domain and can bind to a 
binding sequence in the target genes through this domain38.  Thus, Pim-3 gene 
transcription may be regulated not only by EWS/ETS fusion proteins but also other Ets 
family proteins.  Several independent groups reported that Ets-1, one of the Ets family 
proteins, was expressed in human HCC tissues39, 40.  Ito and colleagues described that 
Ets-1 expression was markedly enhanced in non-cancerous lesions adjacent to HCC 
lesions and suggested that Ets-1 had a crucial role in hepatocarcinogenesis and HCC 
progression during their early phases39.  In line with these observations, we also 
observed that another transcription factor with an ETS-domain, polyomavirus enhancer 
A binding protein-3, was expressed selectively in HCC and that polyomavirus enhancer 
A binding protein-3 induced constitutive gene expression of a pro-angiogenic factor, 
interleukin (IL)-8, in HCC41.  Thus, it is tempting to speculate that a transcription 
factor(s) with an ETS-domain, may induce ectopic Pim-3 gene expression in liver, 
during the course of hepatocarcinogenesis. 
Several lines of evidence demonstrated that the gene expression of Pim-1 and 
Pim-2 could be regulated by IL-6-gp130-mediated signal transducers and activators of 
transcription (STAT) family protein, STAT342, 43.  STAT3 signals can advance cell 
cycles and prevent apoptosis by inducing Pim-1 and c-Myc in lymphomagenesis43.  In 
the liver, IL-6-deficient mice exhibited an impaired liver regeneration after a partial 
hepatectomy44.  Several lines of evidence have revealed that Bcl-xL expression is 
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up-regulated by IL-6-gp130-mediated STAT3 and prevents hepatocyte apoptosis45, 46, 
and that the constitutive activation of STATs observed during oncogenesis can cause a 
permanent alteration in the genetic program46, 47.  These observations suggest that 
STAT3 signals could regulate hepatocyte regeneration also during the course of 
HBV-induced hepatocarcinogenesis.  We observed that Pim-3 gene ablation by RNAi 
attenuated proliferation rates and caused cell death in hepatoma cell lines.  Thus, if 
Pim-3 was also regulated by STAT3, these observations suggest that Pim-3 would also 
be involved in STAT3-mediated prevention of apoptosis and/or cell cycle progression. 
 Pim-1 and Pim-2 are also known as proto-oncogene to be involved in 
lymphomagenesis48, 49.  Because Pim-1 and Pim-2 can induce anti-apoptotic effects21-25, 
Pim-3 may be involved in cell cycle regulation and/or anti-apoptosis.  We also 
observed that gene ablation of Pim-3 caused cell death to human hepatoma cell lines, 
later than 3 days after the transfection.  These results suggest that Pim-3 can regulate 
cell cycle and/or apoptosis process indirectly by phosphorylating a molecule(s) 
upstream in these processes.  Although Pim-1 can phosphorylate several molecules 
such as Cdc25A50, a G1/S cell cycle regulator, Pim-3 could not interact with Cdc25A37.  
Pim-1 can also phosphorylate valosine containing protein (VCP)/p9742, 43, a mammalian 
homolog of Saccaromyces cerevisiae Cdc48p.  Pim-1 can up-regulate further the 
expression of an anti-apoptotic molecule, Bcl-2 and Bcl-xL, by augmenting the 
expression of VCP42, 43.  In HCC tissues and human hepatoma cell lines, evidence is 
accumulating to indicate that Bcl-xL is constitutively expressed and is a major executer 
to prevent apoptosis51-53.  Moreover, VCP was also detected in human HCC tissues54.  
If VCP could be phosphorylated by Pim-3 as well as Pim-1, Pim-3 may exert an 
anti-apoptosis effect by augmenting indirectly the expression of an anti-apoptotic 
molecule, similarly as Pim-1.  Moreover, if the contents of target molecules may differ 
between HuH7 and Hep3B cell lines, these may account for different patterns of the 
effects of Pim-3 gene ablation on the proliferation of these cell lines. 
 The kinase activity of Pim-3 was crucially involved in EWS/ETS-mediated 
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malignant transformation of mouse NIH 3T3 cells37.  Our present observations suggest 
that Pim-3 can regulate anti-apoptosis process and/or cell cycle progression probably by 
modulating molecules involved in these processes.  Accumulating evidence indicated 
that Pim-3 can auto-phosphorylate itself8, 17, but it still remains elusive on physiological 
substrates of Pim-3.  The identification of a substrate(s) may shed novel light on 
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TABLE 1. 
 Identification of genes differentially expressed in pre-malignant lesion of HBsTg mice 
classification description accession number 
up-regulated   
  transcription factors Y box protein 3 AK029441 
  immune system proteins complement component 3 BC043338 
  xenobiotic metabolism ceruloplasmin NM_00775 
 metallothionein II AK002567 
  oncogenes 24p3 (lipocalin 2) X81627 
  metabolism enzymes aldehyde dehydrogenase family 1, subfamily A1 BC044729 
 hemoglobin α, adult chain 1 NM_008218 
 phosphoenolpyruvate carboxy-kinase 1 NM_011044 
 succinate dehydrogenase complex, subunit A flavoprotein BC031849 
  growth factors, cytokines, and chemokines growth differentiation factor 15 (macrophage inhibiting compound-1) NM_011819 
 insulin-like growth factor binding protein 1 NM_008341 
  non-receptor protein kinases serine/threonine kinase pim-3 NM_145478 
  not classified betaKlotho AF178429 
 pol protein XM_196572 
 serine (or cysteine) proteinase inhibitor, clade A, member 6 NM_007618 
  putative proteins hypothetical Esterase/acetylhydrolase structure containing protein NM_026347 
 putative e1 protein AK090127 
 similar to bile acid Coenzyme A: amino acid N-acyltransferase NM_145368 
  est  AW047153 
  BE132832 
  BB168703 
  BM224373 
  unknown fibronectin non-coding region  
 hypothetical protein non-coding region chromosome 5  
down-regulated   
  immune system proteins β2-microglobulin  
 complement component C1SA AF459017 
  extracellular transport/carrier proteins serum amyloid A-1 M13521 
  metabolism enzymes cytochrome P450 4A10 BC031141 
 hemoglobin β, adult major chain  AK027904 
 stearoyl-Coenzyme A desaturase 1 BC007474 
 isocitrate dehydrogenase 1 (NADP+), soluble AK087063 
  not classified endogenous retrovirus 3' LTR  K02892 
 glutatione S-transferase BC009805 
 group1 major urinary protein X03208 
 major urinary protein 1 BC012221 
 major urinary protein 2 BC012259 
27 
 major urinary protein 3 XM_135398 
 major urinary protein 11 and 8 AK011413 
 preimplantation protein 2 AK028563 
 ubiquitin-associated protein 1 NM_023305 
  mitchondrial gene cytochrome oxidase A1 V00711 
  putative proteins archerase AY071852 
 dis3 protein homolog AK032091 
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FIGURE LEGENDS  
 
FIGURE 1.  Semi-quantitative RT-PCR analysis for proto-oncogene Pim family 
mRNA expression in HBsTg mice. 
A.  Total RNAs were extracted from HBsTg mice before (symbol N), 9 (whole liver, 
symbol 9), 15 months (pre-malignant lesions, symbol 15) after splenocyte transfer, or 
transgenic splenocytes transfer (symbol C). 
B.  Total RNAs were extracted from pre-malignant (symbol P) or malignant (symbol 
M) tissues of HBV transgenic mice 15 months after splenocyte transfer. 
Representative results from three independent experiments are shown in the upper 
panels.  The ratios of the PCR product for Pim-3 to GAPDH were determined, and 
relative intensities were calculated to assume the ratio of untreated mice as 1.0.  Then, 
means and SD were calculated and are shown in the lower panels.  Statistical 
significance was evaluated using ANOVA test, and p < 0.05 was accepted as statistically 
significant.  *, p < 0.05 compared with N. 
 
FIGURE 2.  Immunohistochemical analysis of Pim-3 in HBsTg mice.  HBsTg mice 
liver tissues before (A) and 15 months after splenocyte transfer (B, D, and E, non-tumor 
portions; C and F, tumor potions) were immunostained by anti-Pim-3 IgY as described 
in Materials and Methods.  Representative results are shown here.  
B.  Pre-malignant lesion is indicated with arrowheads. 
C.  Tumor portion is indicated with arrowheads. 
D.  The positively stained regenerated proliferating bile ductule.  The arrow indicates 
regenerated proliferating bile ductule. 
E and F.  The positively stained hepatocytes at a higher magnification of the square in 
B and C. 
Original magnification; A to C, x 100; D to F, x 400.  Scale bars are 50 µm. 
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FIGURE 3.  A.  Structure of human Pim-3 cDNA.  The nucleotide and predicted 
amino acid sequences of human Pim-3 are shown.  The nucleotide sequence is 
numbered.  The predicted amino acid sequence is shown in a single-letter code below 
the nucleotide sequence.  The AT-rich motifs are indicated in boxes and highlights.  
The region used as the probe for Northern blot analysis is underlined.   
B. and C.  Amino acid alignment of Pim family proteins.  The amino acid sequences 
of human, rat, and mouse Pim-3s (B) or other members of human Pim family kinases 
(C) were aligned using DNASIS-Mac version 3.0 software (Hitachi Software 
Engineering Co., Ltd., Yokohama, Japan).  The residues identical to human Pim-3 are 
highlighted. 
 
FIGURE 4.  Human Pim-3 mRNA expression in human normal tissues.  Northern 
blot analysis was performed as described in Materials and Methods, and representative 
results are shown here.  sk. muscle, skeletal muscle; PBL, peripheral blood leukocytes.  
GAPDH mRNA expression was analyzed in parallel to evaluate the amount of mRNA 
loaded in each lane. 
 
FIGURE 5.  Immunohistochemical analysis of Pim-3 in HCC tissues.  Human normal 
liver tissue (A) or HCC tissues (B to F) were immunostained by anti-Pim-3 IgY as 
described in Materials and Methods.  Representative results are shown here.  
B.  Precancerous lesions.  The lesions surrounded with arrowheads and arrows are 
precancerous lesions and HCC lesions, respectively. 
C.  Precancerous lesion in the square of B is shown at a higher magnification.  
Arrows indicate regenerated proliferating bile ductules. 
D and E.  The positively stained HCC cells.  E indicates the square in D at a higher 
magnification. 
F.  The positively stained regenerated proliferating bile ductules at a higher 
magnification of the square in D.  Arrows indicate regenerated proliferating bile 
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ductules. 
Original magnification; A, B and D, x 100; C, E, and F, x 400.  Scale bars are 50 µm. 
 
FIGURE 6.  A.  Pim-3 mRNA expression in various human hepatoma cell lines.  
Total RNAs were extracted from human hepatoma cell lines and normal liver tissue.  
RT-PCR was performed, and representative results from three independent experiments 
are shown here.  Analysis for Pim-3 expression was performed without reverse 
transcriptase treatment and the results are shown as non-RT. 
B.  Pim-3 protein expression in HuH7 cells.  HuH7 cells were immunostained by 
anti-Pim-3 IgY (B-a), by pre-immunized IgY (B-b), or by anti-Pim-3 antibodies 
absorbed with the relevant peptide (B-c) as described in Materials and Methods.  
Representative results from three independent experiments are shown here.  Original 
magnification, x 400.  Scale bars are 50 µm. 
 
FIGURE 7.  The effects of endogenous Pim-3 ablation on cell proliferation.   
A.  Semi-quantitative RT-PCR analysis for Pim-3 mRNA levels in siRNA transfected 
cells.  Total RNAs were extracted from the transfectant with Pim-3 siRNA (symbol P), 
Scramble siRNA (symbol S), or no siRNA (symbol N) 2 (Hep3B) or 4 days (HuH7) 
after the transfection as described in Materials and Methods. 
B and C.  Cell proliferation rates were determined on HuH7 (B) and Hep3B (C) cells 
transfected with Pim-3 siRNA (circles), Scramble siRNA (squares), or no siRNA 
(triangles) by WST-1 assay.  Cells were trypsinized and 5 x 103 cells were plated to 
each well of 96-well plate at 2 days after the transfection.  This time point was 
designated as day 0.  The ratios to day 0 were calculated.  Results are expressed as 
means (n = 3), and error bars indicate SD.  Representative results from three 
independent experiments are shown here.  Statistical significance was evaluated using 
ANOVA test, and p< 0.05 was accepted as statistically significant.  *, p < 0.05 
compared with no siRNA samples at the same time point. 
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FIGURE 8.  The effects of endogenous Pim-3 ablation on apoptosis in HuH7 cells.   
A.  HuH7 cells were observed under an inverted microscope at 4 days after the 
transfection with Pim-3 or Scramble siRNA under the same conditions as FIG. 7.  
Representative results from three independent experiments are shown here.  Original 
magnification, x 200.  Scale bars are 50 µm. 
B.  Cell cycles were analyzed at 4 days after the transfection, by using a flow 
cytometry as described in Materials and Methods.  Representative results from three 
independent experiments are shown here. 
C.  Chromatin condensation was analyzed at 4 days after the transfection as described 
in Materials and Methods.  Representative results from three independent experiments 
are shown here.  Results are expressed as means (n = 6), and bars indicate SE.  
Statistical significance was evaluated using ANOVA test, and p < 0.05 was accepted as 
statistically significant.  *, p < 0.05 compared with Scramble siRNA samples. 








